Prokaryotics, Inc.

Prokaryotics, Inc., a biotechnology startup established in 2017, focuses on the discovery and development of innovative therapeutics to combat antimicrobial resistance. The company, headquartered in the United States, has emerged from the licensing of several novel antibiotic programs from Merck & Co., Inc. Its team, comprising former senior scientists from Merck, including the head of the Antimicrobial Early Discovery Unit, is dedicated to optimizing early-stage programs targeting both Gram-negative and Gram-positive bacteria. Prokaryotics has secured worldwide rights to develop, manufacture, and commercialize pre-clinical assets and programs, positioning itself as an authentic antibacterial discovery organization dedicated to addressing the challenge of multidrug-resistant bacteria and the escalating global crisis of antibiotic resistance. The company received a $2.50M grant investment on 08 March 2018 from the National Institutes of Health, reflecting confidence in its mission and approach. Operating at the intersection of the Biopharma, Biotechnology, and Pharmaceutical industries, Prokaryotics aims to pave the way for groundbreaking solutions in the fight against antimicrobial resistance.